COVID-19 is transmitted via droplets or direct contact and infects the respiratory tract resulting in pneumonia and acute respiratory distress syndrome due to excessive production of proinflammatory cytokines leading to widespread tissue damage and multi-organ failure. Targeting cytokines during the management of COVID-19 patients could improve survival rates and reduce mortality. We are presenting a case of a 55 years old female patient with COVID-19 pneumonia with cytokine storm. The patient was treated according to standard treatment guidelines along with Injection Pheniramine maleate. Dramatic improvement in the patient's condition and shorter duration of hospital stay compared to the other cases of severe COVID-19 pneumonia having cytokine storm with longer time of recovery and longer duration of high oxygen demand suggests the role of antihistaminic agents in the treatment of cytokine storm. Hence, we conclude that the inhibition of the inflammatory pathway by an antihistaminic agent (pheniramine maleate) halted the progression of cytokine storm in this patient thus reducing the days in the high dependency unit and favorable clinical outcome.